Intellectual Property

Alzhyme’s technologies are protected through a combination of patents, patent applications and trade secrets. The patent estate encompasses compounds, compositions of matter, and methods and uses for treating Alzheimer’s disease and related dementias.

The value of Alzhyme’s Intellectual Property lies in a combination of the skills and expertise of its key scientist, Professor Martins and his research team, together with key relationships with research institutions and commercial parties working in the relevant field. When Alzhyme was formed in November 2002 all intellectual property was wholly assigned without encumbrance to the new corporate entity.

Screening Methods and the Use of Agents Identified Using the same

Territory	Patent number	Status
United States	10/674,456	Under examination
Europe	02787209.2	Under examination
Australia	2002351880	Granted
United States	11/925,279	Divisional application

Improved Peptide Composition

Territory	Patent number	Status
Australia	2007001767	Has entered National Phase
United States	12/514,738	Has entered National Phase
Europe	07815570.2	Has entered National Phase